Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 1463Pancreatic Neoplasms 833Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 542Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

TIC10 compound 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Glioblastoma × Gastrointestinal × Clear all
NCT02038699 2021-04-30

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 1/2 Withdrawn
BreastCNSGastrointestinalThoracic

Advanced Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡